# Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

> **NCT06880601** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 52 (estimated)

## Conditions studied

- Multiple Myleoma
- Multiple Myeloma in Relapse
- Multiple Myeloma Refractory

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT06880601
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2029-11-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880601, "Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06880601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*